UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions. A key component of its pipeline is UGN-102, currently undergoing Phase III clinical trials. This investigational drug targets various forms of non-muscle invasive urothelial cancer, specifically low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, UroGen is developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds a licensing agreement with Allergan Pharmaceuticals International Limited, enabling the development and commercialization of pharmaceutical products incorporating both RTGel and clostridial toxins. It also partners with Agenus Inc. to advance, produce, and commercialize Agenus's products for intravesical delivery in urinary tract cancer treatment. Furthermore, a strategic research collaboration with MD Anderson aims to progress experimental treatments for high-grade bladder cancer. Established in 2004, UroGen Pharma Ltd. operates out of Princeton, New Jersey.